Form 4: BridgeBio Pharma Director Hannah Valantine Executes Stock Option and Sells Shares

Director Hannah Valantine exercised stock options and sold shares of BridgeBio Pharma, Inc. on March 6, 2025, according to a Form 4 filing.

Summary

• On March 6, 2025, Hannah Valantine, a director of BridgeBio Pharma, Inc., executed a stock option to acquire 12,875 shares of common stock at a price of $16.75 per share.
• Simultaneously, Valantine sold 12,875 shares of common stock at a weighted average price of $32.5825 per share, with prices ranging from $32.17 to $33.01.
• Following these transactions, Valantine directly owns 1,764 shares and indirectly owns 3,433 shares through a spouse.
• The stock option vests in three annual installments starting on June 21, 2024, and ending on June 21, 2026, contingent upon continued service on the Issuer's board of directors.
• The sale was executed under a Rule 10b5-1 sales plan adopted on December 5, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports routine insider trading activity under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Insider transactions are routinely monitored by investors as they can provide insights into management's perspective on the company's valuation and future prospects. Rule 10b5-1 plans are often used to avoid accusations of trading on inside information.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares by a director, but the pre-arranged nature of the sale mitigates concerns about insider information.

Key Dates